Press Center
Aug 6, 2026
Press release
Corporate and finance

Novavax Reports Second Quarter 2026 Financial Results and Operational Highlights

Jul 30, 2026
Corporate and finance

Novavax to Report Second Quarter 2026 Financial Results on August 6, 2026

Jun 1, 2026
Corporate and finance

Novavax to Participate in 2026 Jefferies Global Healthcare Conference

May 7, 2026
Press release
Corporate and finance

Novavax to Participate in BofA Securities 2026 Health Care Conference

Perspectives & Insights

Explore our blog for valuable insights and inspiring stories from our team as we fulfill our vision to spark transformation in global health.

Behind the pipeline
August 11, 2026
Corporate
Partnerships
Research & Development
Video featuring Bob Walker, MD, Executive Vice President, Head of Research & Development
July 22, 2026
Corporate
By Silvia Taylor, Executive Vice President, Chief Corporate Affairs Officer and Head of Novavax Sweden

In the News

See what others are saying about Novavax.

Fierce Biotech

Pfizer pens $530M deal to use Novavax's vaccine adjuvant tech on 2 programs​

Washington Business Journal

Novavax’s stock soars on expected revenue jump from big pharma deals

Reuters

Novavax beats first-quarter revenue estimates on strength in vaccine deals

Pharmaceutical Executive

Expanding the Vaccine Landscape with New Technologies: Q&A with Silvia Taylor

STAT

Facing a brutal run, battered vaccine makers still see cause for hope

PharmaVoice

Has Novavax cracked the code for survival in the vaccine arena?

Note: This section features articles written by external media outlets and journalists.

Media
contact

Phone
(844) 264-8571
Email
media@novavax.com

Images, videos and files for media use

Resources for members of the press.

About Novavax

We tackle some of the world's most significant health challenges by leveraging our scientific expertise in vaccines and cutting-edge technology platform, including protein-based nanoparticles and Matrix-M® adjuvant.